Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials

BACKGROUND: Although existing psoriasis treatments are effective and well tolerated in many patients, there is still a need for new effective targeted treatment options. Tofacitinib is an oral Janus kinase inhibitor that has been investigated in patients with moderate‐to‐severe chronic plaque psoria...

Descripción completa

Detalles Bibliográficos
Autores principales: Strober, B.E., Gottlieb, A.B., van de Kerkhof, P.C.M., Puig, L., Bachelez, H., Chouela, E., Imafuku, S., Thaçi, D., Tan, H., Valdez, H., Gupta, P., Kaur, M., Frajzyngier, V., Wolk, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379291/
https://www.ncbi.nlm.nih.gov/pubmed/30188571
http://dx.doi.org/10.1111/bjd.17149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379291/
https://www.ncbi.nlm.nih.gov/pubmed/30188571
http://dx.doi.org/10.1111/bjd.17149

Ejemplares similares